The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial
Open accessAbstract
OBJECTIVE: Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major depressive disorder. METHOD: In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score ≥4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion (at day 1). RESULTS: The reduction in SSI score at day 1 was 4.96 points greater for the ketamine group compared with the midazolam group (95% CI=2.33, 7.59; Cohen's d=0.75). The proportion of responders (defined as having a reduction ≥50% in SSI score) at day 1 was 55% for the ketamine group and 30% for the midazolam group (odds ratio=2.85, 95% CI=1.14, 7.15; number needed to treat=4.0). Improvement in the Profile of Mood States depression subscale was greater at day 1 for the ketamine group compared with the midazolam group (estimate=7.65, 95% CI=1.36, 13.94), and this effect mediated 33.6% of ketamine's effect on SSI score. Side effects were short-lived, and clinical improvement was maintained for up to 6 weeks with additional optimized standard pharmacotherapy in an uncontrolled follow-up. CONCLUSIONS: Adjunctive ketamine demonstrated a greater reduction in clinically significant suicidal ideation in depressed patients within 24 hours compared with midazolam, partially independently of antidepressant effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine, an NMDA glutamate receptor antagonist, reduced suicidal ideation within 1–4 hours in major depression(71–75) and bipolar disorder.(76, 77)”
From Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review (2021) · cites this paper as [72]
In the citing paper
“Furthermore, ketamine has been reported to also have anti-suicidal and anti-anhedonic actions.14,19,20”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [19]
In the citing paper
“Thirdly, samples were usually small.”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“Firstly, the suicidal risk was often poorly measured (eg, with one single item of a depression scale).”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“Recently, ketamine has been shown to have a rapid effect on depressive symptoms and suicidal ideation after a single dose.8 9 10 11”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“Secondly, response (usually defined as a 50% score reduction on a scale) was the most common outcome rather than remission (that is, complete absence of suicidal ideas).”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“The persistence of the ketamine effect at six weeks of intake is not in line with previous studies10 11 31 and the related meta-analysis,12 but those three studies together analysed only 63 patients.”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [10]
In the citing paper
“Altered expression of glutamate receptor N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainite glutamate receptors is linked to suicidal behavior (129) and may play a role in the rapid-onset antidepressant and antisuicidal effects of ketamine (130-135).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [132]
In the citing paper
“The anti–suicidal ideation effect of ketamine is only partly explained by its antidepressant action, and effects on memory and cognition may also play a role (131-133).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [132]
In the citing paper
“Intravenous ketamine is a rapidly acting treatment that robustly reduces depressive symptoms and suicidal ideation in hours instead of weeks (130-133).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Selective Cortical Undercutting As a Means of Modifying and Studying Frontal Lobe Function in Man
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,374
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Flagged first, then by citations
1 of the 47 references couldn’t be matched to a known paper.
Research works printed but not linked: 7
- Prudic J, 1999, J Clin Psychiatry, 60, 104
- 10.1037/0022-006X.47.2.343 · DOI · Paper page
- First MB, 1994, Structured Clinical Interview for DSM-IV Axis I Disorders (SCID)
- First MB, 1996, Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) (Version 2.0)
- McNair DM, 1981, Manual for the Profile of Mood States
- Levine J, 1986, Psychopharmacol Bull, 22, 343
- Muthén LK, 2012, Mplus User’s Guide
Cited by
Sorted by citations
Items 201–300 of 430
Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review
FREIND, J. M. K., Beserra, F. R., Menezes, B. S., & Mograbi, D. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2248989 · Cited by 12
Zhang, Y., Wei, C., Wang, P., Zheng, L.-C., Cheng, Y., Ren, Z., Jin, Y., Yao, Y., & Liu, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-76226-y · Cited by 15
Is ketamine a litmus test for capacity in assisted dying with depression?
Rosenblat, J. D., & Li, M. (2020) · Psycho-Oncology · doi:10.1002/pon.5586 · Cited by 12
Yao, Z., & McCall, W. V. (2023) · Pharmaceutical Medicine · doi:10.1007/s40290-023-00467-x · Cited by 12
Kavanagh, B. E., Ashton, M. M., Cowdery, S. P., Dean, O. M., Turner, A., Berk, M., Gwini, S. M., Brennan-Olsen, S. L., Koivumaa-Honkanen, H. T., Chanen, A. M., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.10.031 · Cited by 12
Dong, Z., Grunebaum, M. F., Lan, M. J., Wagner, V., Choo, T.-H. J., Milak, M. S., Sobeih, T. M., Mann, J. J., & Kantrowitz, J. T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.653026 · Cited by 12
Self-citationSukhdeo, R., Tamura, J. K., Dri, C. E., & McIntyre, R. S. (2025) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2025.08.001 · Cited by 12
Zhou, C., Zhao, X., Ma, X., Ma, H., Li, R., Hu, G., Wang, H., Peng, Z., & Cai, M. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1114914 · Cited by 12
Doan, L., Li, A., Brake, L., Ok, D., Jee, H. J., Park, H., Cuevas, R., Calvino, S., Guth, A. A., Schnabel, F. R., et al. (2023) · Journal of Pain Research · doi:10.2147/jpr.s389564 · Cited by 15
Ryan, K., & Hosanagar, A. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01432-w · Cited by 11
Hovda, N., Gerrish, W. G., Frizzell, W., & Shackelford, R. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.120 · Cited by 13
Rhee, T. G., Shim, S. R., Popp, J. H., Trikalinos, T. A., Rosenheck, R. A., Kellner, C. H., Seiner, S. J., Espinoza, R. T., Forester, B. P., & McIntyre, R. S. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02366-8 · Cited by 12
Major challenges in youth psychopathology: treatment-resistant depression. A narrative review
Menculini, G., Cinesi, G., Scopetta, F., Cardelli, M., Caramanico, G., Balducci, P. M., Giorgi, F. D., Moretti, P., & Tortorella, A. A. V. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1417977 · Cited by 13
Opioid Receptor μ-1 and Ketamine Effects in a Suicidal Depression Trial
Grunebaum, M. F., Galfalvy, H., Liu, J., Huang, Y., Marcott, S., Burke, A. K., & Mann, J. J. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001237 · Cited by 11
Self-citationHuang, S., Lewis, M. O., Bao, Y., Adekkanattu, P. M., Adkins, L., Banerjee, S., Bian, J., Gellad, W. F., Goodin, A. J., Luo, Y., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164813 · Cited by 11
Sajid, S., Galfalvy, H., Keilp, J. G., Burke, A. K., Mann, J. J., & Grunebaum, M. F. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae017 · Cited by 12
Self-citationCusin, C., Sakurai, H., Bentley, K. H., Pedrelli, P., Foster, S. L., D, M. F. M., & Mischoulon, D. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19050508 · Cited by 11
Calabrese, L. V. (2019) · International Journal of Psychiatry Research · doi:10.33425/2641-4317.1033 · Cited by 11
Zheng, W., Zhou, Y., Wang, C., Lan, X., Zhang, B., Zhou, S., Yan, S., Yang, M., Nie, S., & Ning, Y. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320973794 · Cited by 11
Hans, D., Rengel, A., Hans, J., Bassett, D. L., & Hood, S. D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263149 · Cited by 12
Su, B., Cheng, S., Wang, L., & Wang, B. (2022) · Bioengineered · doi:10.1080/21655979.2022.2059937 · Cited by 12
RetractedClinical trials for rapid changes in suicidal ideation: lessons from ketamine
Ballard, E. D., Fields, J., Farmer, C. A., & Zarate, C. A. (2021) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12663 · Cited by 10
Meyerhoff, J., Kruzan, K. P., Kim, K. A., Orden, K. A. V., & Mohr, D. C. (2022) · Archives of Suicide Research · doi:10.1080/13811118.2022.2096520 · Cited by 10
Anti-Suicidal Effects of Lithium, Ketamine, and Clozapine—A 10-Year Systematic Review
Waszak, P. M., Opalko, J., Olszańska, N., & Zagożdżon, P. (2025) · Pharmaceuticals · doi:10.3390/ph18050742 · Cited by 15
Characterization of suicidal depression: A 1 year prospective study
Nobile, B., Olié, É., Dubois, J., Benramdane, M., Guillaume, S., & Courtet, P. (2022) · European Psychiatry · doi:10.1192/j.eurpsy.2022.16 · Cited by 10
Mitchell, J., Anijärv, T. E., Levenstein, J. M., Hermens, D. F., & Lagopoulos, J. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105279 · Cited by 10
Kitay, B. M., Murphy, E., Macaluso, M., Corlett, P. R., Hershenberg, R., Joormann, J., Martinez‐Kaigi, V., Nikayin, S., Rhee, T. G., Sanacora, G., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115585 · Cited by 13
Deng, Q., Parker, E., Wu, C., Zhu, L., Liu, T. C., Duan, R., & Yang, L. (2024) · Aging and Disease · doi:10.14336/ad.2024.0239 · Cited by 10
The Role of Gut Microbiota in the Antidepressant Effects of Ketamine
Wang, Y., Xu, X., Luo, A., & Yang, C. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_8 · Cited by 10
Elwyn, R., Mitchell, J., Kohn, M. R., Driver, C., Hay, P., Lagopoulos, J., & Hermens, D. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105122 · Cited by 10
Zheng, W., Zhou, Y., Wang, C., Lan, X., & Ning, Y. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.120 · Cited by 10
González‐Castro, T. B., Tovilla‐Zárate, C. A., Juárez‐Rojop, I. E., López‐Narváez, M. L., Pérez‐Hernández, N., Rodrı́guez-Pérez, J. M., & Mendoza, A. D. G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.10.024 · Cited by 12
Wang, J., Liu, H., & Wei, X. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115890 · Cited by 9
Feng, W., Chen, C., Zeng, Y., & Zhang, B. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111152 · Cited by 10
Effects of Ketamine vs. Midazolam in Adolescent Treatment Resistant Depression
Macejova, A., Kovacova, V., Tonhajzerová, I., Višňovcová, Z., Ferencová, N., Mlyncekova, Z., Kukucka, T., & Ondrejka, I. (2024) · Pharmaceuticals · doi:10.3390/ph17121627 · Cited by 10
Cuomo, A., Pardossi, S., Barillà, G., Carmellini, P., Firenzuoli, B., Tarantino, F., Tinturini, R., & Fagiolini, A. M. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.01.059 · Cited by 10
Haikazian, S., McIntyre, R. S., Meshkat, S., Kratiuk, K., Llach, C.-D., Orsini, D. K., Luch, S. D. D., & Rosenblat, J. D. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116691 · Cited by 9
Hippocampal subfield volumes predict treatment response to oral ketamine in people with suicidality
Dutton, M., Boyes, A., Can, A., Mohamed, A. Z., Hajishafiee, M., Shan, Z., Lagopoulos, J., & Hermens, D. F. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.11.040 · Cited by 9
Kang, M. J. Y., Kulcar, E., Chandrasena, R. D., Anjum, M.-R., Fairbairn, J., Hawken, E. R., & Vázquez, G. H. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113645 · Cited by 9
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Pharmaceuticals · doi:10.3390/ph16040634 · Cited by 11
Ketamine in depression and electroconvulsive therapy
Rozet, I. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001039 · Cited by 10
Bloomfield-Clagett, B., Ballard, E. D., Greenstein, D. K., Wilkinson, S. T., Grunebaum, M. F., Murrough, J. W., Mathew, S. J., Phillips, J. L., Fava, M., Sanacora, G., et al. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac055 · Cited by 8
Self-citationOyetunji, A. O., Huelga, C., Bunte, K., Tao, R., & Bellman, V. (2023) · AIMS Public Health · doi:10.3934/publichealth.2023043 · Cited by 11
Mușat, M. I., Ifrim-Predoi, A.-M., Mitran, S. I., Osiac, E., & Cătălin, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083558 · Cited by 8
Ketamine as a Treatment Option for Severe Borderline Personality Disorder
Rogg, H. V., Avram, M., Müller, F., Junghanns, K., Borgwardt, S., & Zurowski, B. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001642 · Cited by 9
Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence
Parincu, Z., & Iosifescu, D. V. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2192402 · Cited by 9
The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review
Ramos, C. S., Thornburg, M., Long, K., Sharma, K., Roth, J., Lacatusu, D., Whitaker, R., Pacciulli, D., Loo, S. M., Manzoor, M., et al. (2022) · Cureus · doi:10.7759/cureus.23647 · Cited by 10
Lamontagne, S. J., Ballard, E. D., & Zarate, C. A. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100450 · Cited by 10
de León-Martínez, V., Kumar, R., Nägele, P., Palanca, B. J., Gott, B. M., Janski, A. M., Zorumski, C. F., & Conway, C. R. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22br14725 · Cited by 8
Lu, B. Y., Agapoff, J. R., Olson, D. J., Williams, S. R., Roller, A., & Goebert, D. A. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.10.050 · Cited by 8
Boldrini, M., & Mann, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00039-3 · Cited by 7
Self-citationMaking Progress in Clinical Trials for Suicide Prevention
Wilkinson, S. T., Bryan, C. J., Alphs, L. D., Canuso, C. M., Ostacher, M. J., Price, R. B., Bloch, M. H., Zarate, C. A., & Rhee, T. G. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4810 · Cited by 7
Shim, S. R., Jeong, H. S., Bommersbach, T. J., Nierenberg, A. A., Zarate, C. A., Kaster, T. S., Correll, C. U., McIntyre, R. S., Krystal, J. H., & Rhee, T. G. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0612 · Cited by 8
Li, W., Chen, L., Su, T., Li, C., Lin, W., Wu, H.-J., Tsai, S., Bai, Y., Tu, P., & Chen, M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.05.024 · Cited by 7
Ladha, K. S., Lee, J., Mattina, G. F., Pazmino‐Canizares, J., Wijeysundera, D. N., Nezhad, F. G., Philip, K., Tassone, V. K., Adamsahib, F., Bhat, V., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297330 · Cited by 7
A scientometric analysis of research on the role of NMDA receptor in the treatment of depression
Chen, X., Wang, X., Li, C., Zhang, Y., Feng, S., & Xu, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1394730 · Cited by 7
Gómez‐Revuelta, M., Fernández-Rodríguez, M., Antón, L. B., & Vázquez-Bourgón, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320981498 · Cited by 7
Therapeutic Use of Hallucinogens
Wiltenburg, V. D., Prado, D. D. R., & Mendes, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-62855-0_35 · Cited by 1
Rethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 7
Self-citationQin, Y., Li, H., Zhang, Y. T., Cao, J., Zhang, W., & Zhang, H. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173590 · Cited by 9
Online news media reporting of ketamine as a treatment for depression from 2000 to 2017
Gallagher, B., Neiman, A., Slattery, M.-C., & McLoughlin, D. M. (2021) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2021.47 · Cited by 7
Weleff, J., Bryant, K. A., Kovacevich, A., & Barnett, B. S. (2022) · Case Reports in Psychiatry · doi:10.1155/2022/1104668 · Cited by 7
Kim, H., Kim, Y., Shin, M., Park, Y., Park, H.-E., D, M. F. M., Mischoulon, D., Park, M. J., Kim, E., & Jeon, H. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.607892 · Cited by 10
Wang, Y., Xu, J., Zhou, X., Che, L., Qiu, M., Liu, Y., Gao, M., & Yang, Z. (2025) · Advanced Science · doi:10.1002/advs.202516024 · Cited by 9
Carmellini, P., Pinzi, M., Rescalli, M. B., & Cuomo, A. (2025) · Brain Sciences · doi:10.3390/brainsci16010018 · Cited by 7
Le, G. H., Wong, S., Johnson, D. E., Lu, A., Orsini, D. K., Chisamore, N., Luch, S. D. D., Rosenblat, J. D., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.121081 · Cited by 6
Gałecki, P., Bliźniewska-Kowalska, K. M., Cubała, W. J., Depukat, A., Mosiołek, A., RYBAKOWSKI, J. K., Samochowiec, J., Sobolewski, B., Szulc, A., & Dudek, D. (2024) · Psychiatria Polska · doi:10.12740/pp/189494 · Cited by 9
Chen-Li, D. C. J., Mansur, R. B., Vincenzo, J. D. D., Chisamore, N., Kaczmarek, E. S., McIntyre, R. S., & Rosenblat, J. D. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116282 · Cited by 7
Su, T., Cheng, L., Tu, P., Chen, L., Lin, W., Li, C., Bai, Y., Tsai, S., & Chen, M. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116377 · Cited by 6
Is psilocybin an effective antidepressant and what is its Mechanism of action?
Mann, J. J. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100906 · Cited by 7
Self-citationChen, M., Su, T., Li, C., Lin, W., Wu, H.-J., Tsai, S., Bai, Y., Mao, W., & Tu, P. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01735-2 · Cited by 6
Tashakkori, M., Ford, A. H., Dragović, M., Gabriel, L., & Waters, F. (2020) · Australasian Psychiatry · doi:10.1177/1039856220961642 · Cited by 6
Li, J., Ma, L., Sun, H., Li, M., Cao, Y., Peng, Y., & Xu, J. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01920-x · Cited by 5
Motamed, M., Fathi, A., Hajikarim‐Hamedani, A., & Alaghband‐Rad, J. (2025) · Annals of General Psychiatry · doi:10.1186/s12991-025-00572-y · Cited by 5
Inflammation and treatment strategies for suicidal behavior
Behera, C., Gupta, S., Shelton, R. C., & Dwivedi, Y. (2026) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2026.2659772 · Cited by 5
Kovacova, V., Macejova, A., Tonhajzerová, I., Višňovcová, Z., Ferencová, N., Mlyncekova, Z., Kukucka, T., Farský, I., Nosáľ, S., & Ondrejka, I. (2024) · Pharmaceuticals · doi:10.3390/ph17030358 · Cited by 6
Deka, A., Joseph, E., Sharma, N., Berhanu, T., & Kaplan, J. (2024) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000787 · Cited by 5
Learning how to make use of dissociative therapies
Mathai, D. S. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2406329 · Cited by 5
Penaluna, B. K., Voort, J. L. V., Bobo, W. V., Pazdernik, V., Achtyes, E. D., Goes, F. S., Greden, J. F., Parikh, S. V., Frye, M. A., & Singh, B. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119414 · Cited by 5
Tamman, A. J. F., Anand, A., & Mathew, S. J. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2049754 · Cited by 6
Chaudhary, P., Shah, P., & Mehta, P. (2022) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_231_21 · Cited by 5
Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression.
Fancy, F., Rodrigues, N. B., Vincenzo, J. D. D., Chau, E., Sethi, R., Husain, M. I., Gill, H., Tabassum, A., McKenzie, A., Phan, L., et al. (2023) · Focus · doi:10.1176/appi.focus.23021022 · Cited by 26
Qiu, L., Chen, X., Fu, J., Chen, X., & Wang, X. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06035-0 · Cited by 9
Clinical use of ketamine in psychiatric disorders
Dehestani, S., Mohammadpour, A. H., Sadjadi, S. A., Sathyapalan, T., & Sahebkar, A. (2022) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2022.05.008 · Cited by 6
Alarcón-Vásquez, Y., Bahamón, M., Herrera, A., González-Gutiérrez, O., Rubio-Castro, R., Hernández-Cervantes, Q., & Gómez-Maqueo, E. L. (2019) · Revista Iberoamericana de Diagnóstico y Evaluación - e Avaliação Psicológica · doi:10.21865/ridep51.2.07 · Cited by 5
Infusing Hope Into the Treatment of Suicidality: a Review of Ketamine’s Effects on Suicidality
Rengasamy, M. L., Hsiung, K. S., & Price, R. B. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00184-3 · Cited by 5
Irwin, M. N., & VandenBerg, A. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.05.200 · Cited by 7
Sajid, S., Mann, J. J., & Grunebaum, M. F. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03255-0 · Cited by 6
Self-citationQureshi, M. M., Silman, D., Gadelrab, R., Stein, H., Carmellini, P., Duncan, G., Mehta, M. A., Young, A. H., Reilly, C., & Juruena, M. F. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251340925 · Cited by 4
Fong, T. H., Li, T., Ma, X., Cai, X., & Zhou, Q. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02200-5 · Cited by 4
Antidepressiva und Selbstgefährdung: ein Widerspruch?
Hatzinger, M. (2019) · Praxis · doi:10.1024/1661-8157/a003235 · Cited by 4
Titone, M. K., Hunt, C., Bismark, A. W., Nokes, B. T., Lee, E., Ramanathan, D., Park, J., & Colvonen, P. J. (2023) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10746 · Cited by 4
Knyahnytska, Y., Zomorrodi, R., Kaster, T. S., Voineskos, D., Trevizol, A. P., & Blumberger, D. M. (2021) · JMIR Research Protocols · doi:10.2196/30163 · Cited by 4
Sato, A., Sugawara, N., Kawamata, Y., & Yasui‐Furukori, N. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12428 · Cited by 4
Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Więdłocha, M., Marcinowicz, P., Komarnicki, J., Tobiaszewska, M., Dębowska, W., Dębowska, M. D., & Szulc, A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1398859 · Cited by 8
Antidepressant Actions of Ketamine and Its Two Enantiomers
Chang, L., Wei, Y., & Hashimoto, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_7 · Cited by 4
Bruno Giros, A. (2018) · médecine/sciences · doi:10.1051/medsci/2018242 · Cited by 4
Suicide research and prevention: we need new, innovative approaches
Sher, L. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13060 · Cited by 4
Xu, R., Pan, Y., Gorenflo, M. P., Davis, P. B., Kaelber, D. C., & Luca, S. M. D. (2023) · Research Square · doi:10.21203/rs.3.rs-3207199/v1 · Cited by 4
Ketamine for unipolar depression: A systematic review of efficacy and safety
Peiris, T. E., Pokhrel, A., & Paudel, Y. (2025) · Australasian Psychiatry · doi:10.1177/10398562251328805 · Cited by 3
Metadata
- Authors
- Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., & Mann, J. J.
- Affiliations
- Columbia University Irving Medical Center (US)
- From the Molecular Imaging and Neuropathology Division, Department of Psychiatry, and the Department of Anesthesiology, Columbia University Medical Center and New York State Psychiatric Institute, New York.
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2018-04-01
- Volume
- 175
- Issue
- 4
- Pages
- 327-335
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC5880701
- OpenAlex
- W2771797851
- Cited by
- 431
- References
- 47
- Citations by year
- 2026: 31 · 2025: 45 · 2024: 52 · 2023: 57 · 2022: 62 · 2021: 54 · 2020: 55 · 2019: 43 · 2018: 31
- FWCI
- 24.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH096784)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, midazolam, suicidal ideation, major depressive disorder, rapid-acting antidepressants, adjunctive pharmacotherapy, suicide risk reduction, antidepressant effects, mediation analysis
- MeSH terms
- Behavior Rating Scale, Suicide Prevention, Adult, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Infusions, Intravenous, Ketamine, Male, Midazolam, Middle Aged, Suicide, Young Adult, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
